CDl51、c-Met及整合素仪α3、α6在胰腺导管腺癌中的表达及其与预后的关系

Expression of CDl5l, c-Met, integrin alpha 3, alpha 6 and the prognostic significance in pancreatic ductal adenocarcinoma

目的探讨CD蚓、c-Met和整合素仪3、拍蛋白在胰腺导管腺癌中的表达及其与预后的关系。方法用免疫组化法检测71例胰腺导管腺癌及10例正常胰腺组织中CD151、c-Met和整合素仪3、嘶蛋白的表达，分析它们与临床病理特征及患者预后的关系。结果CD151、c-Met和整合素仪3、面在71例胰腺导管腺癌组织中的表达阳性率分别为81．69％（58／71）、69．01％（49／71）、69．01％（49／71）和84．51％（60／71），而正常胰腺组织均未表达。CD151和c-Met的表达与肿瘤的TNM分期、淋巴结转移显著相关（P值均〈0．05）。CD151，的表达与c-Met及整合素α3、α6的表达呈正相关（r=0．583，P=0．000；r=0．457；P=0．000；r=0．671；P=0．000）。单因素分析显示，CD151、c-Met、整合素α3和α6的表达与预后有关（P值均〈0．05）。多因素分析表明，CD151、c-Met是患者术后生存时间的独立预后因子。结论CD151、c-Met及整合素α3、α6在胰腺癌的发展、转移及预后发挥重要作用，CD151、c-Met可考虑作为临床评价胰腺癌生物学行为及评估预后的指标。

Objective To investigate the expression and prognostic significance of CD151 , c-Met and integrin alpha 3, alpha 6 in pancreatic ductal adenocarcinoma （PDAC）. Methods The expression of CD151, c-Met and integrin alpha3, alpha6 in 71 patients with PDAC and 10 samples of normal pancreas tissues were detected by immunohistoehemistry, and the relationship between the expression of CD151 , c-Met and integrin alpha 3, alpha 6 and the clinicopathologieal features, prognosis of these patients was analyzed. Results The positive expression rates of CDls1 , e-Met and integrin alpha 3, alpha 6 in PDAC were 81.69% （ 58/71 ） , 69.01% （49/71）, 69.01% （49/71） and 84.51% （60/71）, and there was no expression in normal pancreas tissues. The expressions of CD151, c-Met were significantly associated with TNM stage and lymph node metastasis （P 〈 0.05）. The expression of CDl51 was positively correlated with the expressions of c-Met and integriu alpha3, alpha6 （r = O. 583, P = 0.000, r = 0.457 ; P = O. 000, r = 0.671 ; P = 0.000）. Univariate analysis suggested the expression of CD151 , c-Met and integrin alpha3, alpha6 was associated with survival （P 〈 0.05 ）. Multivariate analysis suggested the expression of CDl51 , c-Met was the independent prognostic factor for post-operative survival. Conclusions CD151 , c-Met and integrin alpha3, alpha6 play a role in the development, metastasis and prognosis of PDAC, and they might be new markers to predict biological behavior and the prognosis of PDAC patients.